MetaCap

First Tracks Biotherapeutics (TRAX) vs Zymeworks (ZYME)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zymeworks is the larger company by market cap ($1.81 billion vs $1.75 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TRAX+119.16%ZYME+1.16%
+185%+78%-29%
Apr 6, 20261 yearNov 20, 2026
TRAX+77.19%ZYME-0.68%
+111%+36%-39%
Apr 6, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TRAX versus ZYME key metrics
MetricTRAXZYME
Share price$41.64$26.14
Market cap$1.75B$1.81B
1-day change-6.34%-2.68%
YTD return—-0.72%
1-year return—+8.83%
5-year return—+34.05%
P/E ratio (TTM)—49.32
Forward P/E—54.95
EPS (TTM)$-4.71$0.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$105.97M
Revenue growth (YoY)—+38.87%
Net income (latest FY)—$-81.13M
Operating margin—-87.34%
Net margin—-76.56%
52-week high$54.78$31.97
52-week low$14.72$21.52
Distance from 52-week high-23.99%-18.24%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+80.52%+65.61%
Average volume826.70K1.09M
Shares outstanding42.02M68.70M
Employees104279
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About First Tracks Biotherapeutics

TRAX stock →

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 104 employees

About Zymeworks

ZYME stock →

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees

TRAX vs ZYME FAQ

Which is bigger, First Tracks Biotherapeutics or Zymeworks?

Zymeworks (ZYME) is larger, with a market capitalization of $1.81B compared with $1.75B for First Tracks Biotherapeutics (TRAX).

Are First Tracks Biotherapeutics and Zymeworks in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons